BeiGene (NASDAQ:BGNE) Issues Earnings Results

BeiGene (NASDAQ:BGNE) posted its earnings results on Tuesday. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04), Briefing.com reports. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share.

BeiGene Trading Up 3.4 %

BGNE traded up $6.52 during trading on Wednesday, reaching $200.16. The company had a trading volume of 21,251 shares, compared to its average volume of 263,926. The firm’s 50-day simple moving average is $212.67 and its 200 day simple moving average is $181.34. The company has a market cap of $19.50 billion, a price-to-earnings ratio of -39.40 and a beta of 0.63. BeiGene has a 12-month low of $126.97 and a 12-month high of $248.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

Wall Street Analysts Forecast Growth

BGNE has been the topic of a number of recent analyst reports. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Finally, Citigroup boosted their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, BeiGene currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.21.

Insider Buying and Selling

In other BeiGene news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other BeiGene news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of BeiGene stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,070 shares of company stock valued at $4,901,050. 7.43% of the stock is owned by corporate insiders.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.